IE 11 is not supported. For an optimal experience visit our site on another browser.

FDA head calls for investigation into approval of controversial Alzheimer’s drug


In a letter, FDA Commissioner Janet Woodcock wrote that she’s concerned about “contacts between representatives from Biogen and FDA during the review process, including some that may have occurred outside of the formal correspondence process.”